HYPREVENTION
Created in 2010
Up & running (A)
Existing signals show a regular activitySocial networks
57 3,057Activities
Technologies
Entity types
Location
Av. du Haut Lévêque, 33604 Pessac, France
Pessac
France
Employees
Scale: 2-10
Estimated: 12
Engaged catalyst
1
0 0Added in Motherbase
3 years, 9 months ago
Value proposition
Strutplasty pioneer, address fragile bone.
Founded in 2010 by Cécile Vienney (CEO) and 3 orthopedic surgeons, Hyprevention is a French start-up located in France that develops, manufactures and markets implantable medical devices to reinforce weaken bone by osteoporosis or cancer thanks to the STRUTPLASTY® Technology.
In 2021, Hyprevention INC was established in New-York - USA to promote V-STRUT© Vertebral Implant FDA cleared.
www.hyprevention.com
www.hypreventionusa.com
V-STRUT© Vertebral Implant is indicated to treat vertebral fractures. The device is made of PEEK polymer, close to normal bone, and presents a pedicle anchorage to reinforce the full vertebrae. It is a unique solution on the market aiming to rebalance antero-posterior loading and stress.
With aging, bone quality decreases due to osteoporosis, increasing the risk of vertebral compression fractures). Osteoporosis is the most common disease affecting the elderly population. As a result, the vertebral body is at risk of fracture with about 750 000 vertebral compression fractures per year in the US alone among which 250 000 require treatment.
Y-STRUT® Hip Implant (not available in US) is intended to prevent a contra-lateral fracture in patients at risk due to bone fragility linked to osteoporosis. Implementation of a contralateral Y-STRUT is performed during the same anesthesia as practiced for the treatment of the original fracture. The duration of hospitalization remains unchanged. Contralateral Y-STRUT requires no specific rehabilitation.
Hip fracture affects more than 2 million people worldwide every year. This number will reach more than 6 million in 2050, due to an aging and increasing population. At 1 year, 9% of patients will have a contra-lateral fracture, at 5 years this rises to 20%. After a second contralateral fracture, loss of autonomy is almost certain to prevent a return home. Mortality is multiplied by 2.
The prevention of hip fracture improves the quality of life of older people by allowing them to retain their autonomy.
Medical device manufacturer and distributor, orthopaedic surgical implant, Orthopaedics, spinal implant, and spine surgeryOriginal language
Pionnier de la STRUTPLASTY pour le renforcement biomécanique des os fragilisés.
Founded in 2010 by Cécile Vienney (CEO) and 3 orthopedic surgeons, Hyprevention is a French start-up located in France that develops, manufactures and markets implantable medical devices to reinforce weaken bone by osteoporosis or cancer thanks to the STRUTPLASTY® Technology.
In 2021, Hyprevention INC was established in New-York - USA to promote V-STRUT© Vertebral Implant FDA cleared.
www.hyprevention.com
www.hypreventionusa.com
V-STRUT© Vertebral Implant is indicated to treat vertebral fractures. The device is made of PEEK polymer, close to normal bone, and presents a pedicle anchorage to reinforce the full vertebrae. It is a unique solution on the market aiming to rebalance antero-posterior loading and stress.
With aging, bone quality decreases due to osteoporosis, increasing the risk of vertebral compression fractures). Osteoporosis is the most common disease affecting the elderly population. As a result, the vertebral body is at risk of fracture with about 750 000 vertebral compression fractures per year in the US alone among which 250 000 require treatment.
Y-STRUT® Hip Implant (not available in US) is intended to prevent a contra-lateral fracture in patients at risk due to bone fragility linked to osteoporosis. Implementation of a contralateral Y-STRUT is performed during the same anesthesia as practiced for the treatment of the original fracture. The duration of hospitalization remains unchanged. Contralateral Y-STRUT requires no specific rehabilitation.
Hip fracture affects more than 2 million people worldwide every year. This number will reach more than 6 million in 2050, due to an aging and increasing population. At 1 year, 9% of patients will have a contra-lateral fracture, at 5 years this rises to 20%. After a second contralateral fracture, loss of autonomy is almost certain to prevent a return home. Mortality is multiplied by 2.
The prevention of hip fracture improves the quality of life of older people by allowing them to retain their autonomy.
Home-usa - Hyprevention USA
https://hypreventionusa.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 Up Grade Nouvelle-Aquitaine Civic and Social Organizations | Up Grade Nouvelle-Aquitaine Civic and Social Organizations | Not capitalistic Not partnership Event 17 Sep 2018 | | |